Europe - Frankfurt Stock Exchange - FRA:9VC - NL0015000DX5 - Common Stock
The current stock price of 9VC.DE is 3.827 EUR. In the past month the price increased by 2.05%. In the past year, price increased by 165.49%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.95 | 202.21B | ||
| 1SAN.MI | SANOFI | 10.95 | 202.21B | ||
| SAN.PA | SANOFI | 10.88 | 200.83B | ||
| MRK.DE | MERCK KGAA | 13.63 | 50.56B | ||
| UCB.BR | UCB SA | 37.73 | 47.11B | ||
| UNC.DE | UCB SA | 37.68 | 47.05B | ||
| BAYN.DE | BAYER AG-REG | 6.86 | 35.97B | ||
| 1BAYN.MI | BAYER AG-REG | 6.8 | 35.65B | ||
| IPN.PA | IPSEN | 11.83 | 10.18B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 23.99 | 9.88B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 103.85 | 9.61B | ||
| VIRP.PA | VIRBAC SA | 19.61 | 2.85B |
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI BECKLEY NV
Prof. J.H.Bavincklaan 7
Amstelveen NOORD-HOLLAND NL
Employees: 54
Phone: 31207932536
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
The current stock price of 9VC.DE is 3.827 EUR. The price decreased by -0.18% in the last trading session.
9VC.DE does not pay a dividend.
9VC.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 9VC.DE.
The Revenue of ATAI BECKLEY NV (9VC.DE) is expected to grow by 468.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ATAI BECKLEY NV (9VC.DE) will report earnings on 2026-03-16, after the market close.
ChartMill assigns a technical rating of 7 / 10 to 9VC.DE. When comparing the yearly performance of all stocks, 9VC.DE is one of the better performing stocks in the market, outperforming 98.14% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE. While 9VC.DE has a great health rating, there are worries on its profitability.
Over the last trailing twelve months 9VC.DE reported a non-GAAP Earnings per Share(EPS) of -0.7.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.24% | ||
| ROE | -93.44% | ||
| Debt/Equity | 0 |
17 analysts have analysed 9VC.DE and the average price target is 10.57 EUR. This implies a price increase of 176.08% is expected in the next year compared to the current price of 3.827.
For the next year, analysts expect an EPS growth of 30.67% and a revenue growth 468.61% for 9VC.DE